spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  p53 

 HSMN NewsFeed - 21 Nov 2022
Diadem Builds Out Executive Team As It Prepares for Commercialization of Its AlzoSure(R) Predict Prognostic Test for Alzheimer's Disease
Diagnostics Neurology Personnel
 HSMN NewsFeed - 1 Feb 2021
New Scientific Publications Show Diadem's Blood-Based AlzoSure(R) Biomarker Test Can Predict Which Patients Will Progress to Alzheimer's Disease Years Before Symptoms Occur
Diagnostics Neurology
 HSMN NewsFeed - 7 Sep 2020
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2020
AbbVie Receives European Commission Approval of VENCLYXTO(R) Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jan 2020
AbbVie Receives Positive CHMP Opinion for VENCLYXTO(R) as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Dec 2019
Fluxion Launches Three New Spotlight(TM) Liquid Biopsy NGS Panels
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 5 Aug 2019
Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Apr 2019
Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Mar 2019
Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Feb 2019
Aprea Therapeutics Adds New Investor to Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Sep 2018
Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Aug 2018
Actavalon Announces Appointments of Dr. John Hood to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Jul 2018
Ascentage Pharma Raises $150 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Jun 2018
AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2018
IDEAYA Biosciences Appoints Paul Stone, J.D., as Senior Vice President and General Counsel, Head of Operations and Mark Lackner, Ph.D. as Vice President, Head of Biomarkers and Synthetic Lethal Biology
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Mar 2018
PMV Pharma Appoints Salim Yazji, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Dec 2017
PMV Pharma Appoints Winston Kung as COO & CFO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Apr 2016
FDA Grants Orphan Drug Designation For VAL-083 In Ovarian Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Mar 2016
Karolinska Development's Portfolio Company Aprea Raises SEK 437 Million
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 26 Feb 2016
AbbVie Receives EMA Orphan Drug Designation for Investigational Compound Venetoclax for the Treatment of Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jan 2016
Cellceutix Releases Data Used in Receiving FDA Orphan Drug Designation of Kevetrin for Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2016
AbbVie's Venetoclax Receives Breakthrough Therapy Designation from FDA in Combination with Rituximab for the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Oct 2014
Aileron Therapeutics Expands Senior Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Oct 2014
Aileron Therapeutics Secures $33 Million in Series E Financing to Advance Its First-In-Class Cancer Drug
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Dec 2013
Cellceutix Files Orphan Drug Designation Application for Brilacidin for Oral Mucositis with US FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2013
Senhwa Biosciences Raises $17M Series B
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Oct 2013
Lorus Therapeutics Appoints New Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Aug 2013
GeneDx Introduces Advanced Genetic Test Panels for Inherited Cancer Including Breast and Colon Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 14 Jan 2013
Aileron Therapeutics Secures $12 Million for First-Ever Stapled Peptide Clinical Trial
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 25 Sep 2012
Life Technologies Launches Pervenio(TM) Lung RS, a Risk Stratification Test for Early Stage Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 18 Jul 2012
NeoGenomics Significantly Expands Molecular Testing Menu and Launches NeoTYPE(TM) Cancer Profile Panels
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 7 May 2012
Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
Diagnostics FDA
 HSMN NewsFeed - 6 Mar 2012
Abbott and Merck Collaborate to Develop Companion Diagnostic Test for Investigational Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 22 Aug 2011
FDA Clears Abbott's Genetic FISH Panel for Leukemia Patient Prognosis
Diagnostics Oncology FDA
 HSMN NewsFeed - 3 Nov 2010
Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jun 2010
Myriad Pharmaceuticals Announces Intent to Focus on Oncology Portfolio
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2010
Ascenta Therapeutics Licenses Cancer Drug Candidates to sanofi-aventis
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 19 Apr 2010
Myriad Pharmaceuticals Announces Termination of Merger Agreement With Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Apr 2010
Myriad Pharmaceuticals Receives Notice of Javelin's Intent to Terminate Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Feb 2010
Roche Collaborates with Merck on Developmental Test for Cancer-Related Gene Mutation
Diagnostics Oncology
 HSMN NewsFeed - 16 Feb 2010
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Dec 2009
Myriad Pharmaceuticals to Acquire Javelin Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Aug 2009
Aperio Receives Second FDA Clearance for HER2 Image Analysis Application for Breast Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 5 May 2009
Clarient Launches New Breast Cancer Test
Diagnostics Oncology
 HSMN NewsFeed - 2 Sep 2008
Introgen Receives Notice ADVEXIN(R) U.S. BLA Not Sufficiently Complete to File
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2008
Gemin X Pharmaceuticals Appoints Peter R. Dolan to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jun 2008
Introgen Submits ADVEXIN(R) Regulatory Applications in the U.S. and Europe
Biopharmaceuticals Oncology FDA Regulatory
 HSMN NewsFeed - 16 Jun 2008
IRX Therapeutics Names Scott M. Freeman, M.D. Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jun 2008
Senior Pharmaceutical Executive, Glenn J. Gormley, M.D., Ph.D., to Lead Gemin X Pharmaceuticals as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 May 2008
ADVEXIN(R) Improves Survival in Recurrent, Refractory Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing
 HSMN NewsFeed - 20 Dec 2007
Introgen Plans to Expand Biomarker Database in Phase 3 Trials and File BLA and MAA for ADVEXIN in Advanced Head and Neck Cancer in First Half of 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2007
Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2007
Introgen's ADVEXIN Advances as Marketing Authorization Application is Accepted for Review in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Nov 2007
Gendux Announces Acceptance of Its ADVEXIN Marketing Authorization Application for Review by the EMEA
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Nov 2007
Introgen Therapeutics Highlights Summary ADVEXIN Data at the Third International Workshop on Mutant p53 and the Symposium on Li-Fraumeni Syndrome
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Nov 2007
Introgen and Gendux Submit First Marketing Authorization Application for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2007
Gemin X Pharmaceuticals, Inc. Appoints Eric Roberts to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Sep 2007
Introgen Presents Biomarker Data Demonstrating Abnormal p53 Predicts ADVEXIN Efficacy in Head and Neck, Lung, Prostate and Li-Fraumeni Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
Introgen's ADVEXIN Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Apr 2007
Celera and LabCorp(R) Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays
Diagnostics Oncology Licensing
 HSMN NewsFeed - 26 Feb 2007
GSK Initiates First Global Phase III Study of TYKERB(R) (lapatinib) in Head and Neck Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Celera Presents Data Validating Its Metastasis Score as a Molecular Prognostic Tool in Breast Cancer
Diagnostics Oncology
 HSMN NewsFeed - 9 Jan 2007
AVI BioPharma and Eleos Announce Cross-License Agreement for p53 Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Dec 2006
Introgen Announces New Clinical Data Confirming ADVEXIN(R) Survival Benefit
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Abbott Introduces CE-Marked DNA Tests in Europe for the Detection of Chromosomal Abnormalities Associated With Leukemia
Diagnostics Oncology
 HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2006
Introgen Obtains Exclusive License to Therapies Combining Epidermal Growth Factor Drugs and Tumor Suppressor Genes
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 31 Oct 2006
Introgen Therapeutics and Gendux AB Announce Agreement With European Medicines Agency to File for ADVEXIN Approval Under Exceptional Circumstance Rules
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2006
Introgen's ADVEXIN Molecular Targeted Therapy Is Active in Multiple Cancers; ADVEXIN Regulatory Program Advances
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Oct 2006
TriPath Imaging Receives FDA 510(k) Clearance for p53 Application for Ventana Image Analysis System
Diagnostics Oncology FDA
 HSMN NewsFeed - 4 Aug 2006
Reata Announces Closing of $22.6 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Jul 2006
Genzyme Launches New Diagnostic Test for Common Blood Cancer
Diagnositcs Oncology
 HSMN NewsFeed - 21 Jun 2006
Access Pharmaceuticals Provides Update on Strategic Oncology Focus
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Jun 2006
Access Pharmaceuticals Provides Update on Strategic Oncology Focus; ProLindac(TM) and MuGard(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2006
Introgen's ADVEXIN p53 Therapy Demonstrates Clinical Benefit in Inherited Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 May 2006
Introgen to Announce Important New Clinical Data for ADVEXIN Cancer Therapy at Major Medical Meetings
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2006
Gendux AB and Introgen Therapeutics File European Orphan Drug Designation for ADVEXIN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 May 2006
Introgen's ADVEXIN p53 Therapy Provided to Cancer Patients With Li-Fraumeni Syndrome
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Apr 2006
Reata Announces Licensing of Novel Class of Anti-Inflammatory Compounds; Drugs Have Broad Potential Across Multiple Therapeutic Areas
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Mar 2006
Phase I/II Clinical Data Demonstrate Safety and Antitumor Activity of Introgen's ADVEXIN(R) in Patients With Advanced Esophageal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2006
Recent FDA Action Validates ADVEXIN(R) Registration Strategy; Introgen Encouraged By Approval of Erbitux(R) for Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 23 Feb 2006
Introgen p53 Therapy Patent Is Affirmed in Europe Following Opposition By Schering-Plough
Biopharmaceuticals Oncology Litigation
 HSMN NewsFeed - 21 Feb 2006
Signet Laboratories, Inc. and AsymmetRx, Inc. Announce Exclusive Agreement for Distribution of FDA 510(k) Cleared Diagnostic Tests ('Prostate-63') for the Diagnosis of Prostate Cancer Using p63
Diagnostics Oncology Distribution
Return to NewsFeed  

 Additional items found! 49

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 49 additional stories matching:
p53
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.